Sign in or create an account to add this stock to your watchlist.
About Proteostasis Therapeutics (NASDAQ:PTI)
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis and other diseases caused by an imbalance in the proteostasis network. Its lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class, which is in Phase II study. The company is also involved in developing PTI-801, a corrector molecule; and PTI-808, a potentiator molecule that have been completed Phase I Study. It has a collaboration agreement with Astellas Pharma Inc. Astellas Pharma, Inc. to research and identify therapies targeting the UPR pathway. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PTI
CUSIPN/A
Phone617-225-0096
Debt
Debt-to-Equity RatioN/A
Current Ratio8.09
Quick Ratio8.09
Price-To-Earnings
Trailing P/E Ratio-2.12
Forward P/E Ratio-2.36
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.34 million
Price / Sales33.72
Cash FlowN/A
Price / CashN/A
Book Value$2.08 per share
Price / Book2.40
Profitability
EPS (Most Recent Fiscal Year)($2.34)
Net Income$-59,430,000.00
Net Margins-1,052.40%
Return on Equity-101.43%
Return on Assets-73.96%
Miscellaneous
Employees52
Outstanding Shares36,080,000
Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions
What is Proteostasis Therapeutics' stock symbol?
Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."
How were Proteostasis Therapeutics' earnings last quarter?
Proteostasis Therapeutics Inc. (NASDAQ:PTI) announced its earnings results on Wednesday, May, 9th. The company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.53) by $0.21. Proteostasis Therapeutics had a negative net margin of 1,052.40% and a negative return on equity of 101.43%. View Proteostasis Therapeutics' Earnings History.
What price target have analysts set for PTI?
4 equities research analysts have issued 12 month price targets for Proteostasis Therapeutics' shares. Their predictions range from $8.00 to $25.00. On average, they expect Proteostasis Therapeutics' share price to reach $14.75 in the next year. View Analyst Ratings for Proteostasis Therapeutics.
Who are some of Proteostasis Therapeutics' key competitors?
Some companies that are related to Proteostasis Therapeutics include Rigel Pharmaceuticals (RIGL), Five Prime Therapeutics (FPRX), Odonate Therapeutics (ODT), Ziopharm Oncology (ZIOP), Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO), Aclaris Therapeutics (ACRS), BeyondSpring (BYSI), Lannett (LCI), Geron (GERN), Prothena (PRTA), Akebia Therapeutics (AKBA), ChemoCentryx (CCXI), AC Immune (ACIU) and CannTrust (CNTTF).
Who are Proteostasis Therapeutics' key executives?
Proteostasis Therapeutics' management team includes the folowing people:
- Ms. Meenu Chhabra, Pres, Chief Exec. Officer & Director (Age 46)
- Ms. Helen M. Boudreau, CFO, Principal Accounting Officer & Treasurer (Age 52)
- Dr. Po-Shun Lee M.D., Exec. VP & Chief Medical Officer (Age 49)
- Dr. Marija Zecevic, Chief Operating Officer (Age 44)
- Dr. Benito Munoz M.Sc., Ph.D., Chief Scientific Officer (Age 56)
When did Proteostasis Therapeutics IPO?
(PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.
Has Proteostasis Therapeutics been receiving favorable news coverage?
News articles about PTI stock have trended positive on Monday, according to Accern Sentiment. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Proteostasis Therapeutics earned a news sentiment score of 0.28 on Accern's scale. They also assigned press coverage about the company an impact score of 46.56 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Proteostasis Therapeutics' major shareholders?
Proteostasis Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bailard Inc. (1.49%), Lord Abbett & CO. LLC (1.33%), DAFNA Capital Management LLC (0.74%), Millennium Management LLC (0.59%), Franklin Resources Inc. (0.32%) and Doheny Asset Management CA (0.19%). Company insiders that own Proteostasis Therapeutics stock include Cormorant Asset Management, Ll, Enterprise Associates 12 New, Fmr Llc, Franklin M Berger and Meenu Chhabra. View Institutional Ownership Trends for Proteostasis Therapeutics.
Which institutional investors are selling Proteostasis Therapeutics stock?
Which institutional investors are buying Proteostasis Therapeutics stock?
PTI stock was purchased by a variety of institutional investors in the last quarter, including Bailard Inc., Lord Abbett & CO. LLC, DAFNA Capital Management LLC, Doheny Asset Management CA, Tibra Equities Europe Ltd, Barclays PLC, Bayesian Capital Management LP and Element Capital Management LLC. Company insiders that have bought Proteostasis Therapeutics stock in the last two years include Cormorant Asset Management, Ll, Enterprise Associates 12 New, Franklin M Berger and Meenu Chhabra. View Insider Buying and Selling for Proteostasis Therapeutics.
How do I buy shares of Proteostasis Therapeutics?
Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Proteostasis Therapeutics' stock price today?
One share of PTI stock can currently be purchased for approximately $4.99.
How big of a company is Proteostasis Therapeutics?
Proteostasis Therapeutics has a market capitalization of $178.96 million and generates $5.34 million in revenue each year. The company earns $-59,430,000.00 in net income (profit) each year or ($2.34) on an earnings per share basis. Proteostasis Therapeutics employs 52 workers across the globe.
How can I contact Proteostasis Therapeutics?
Proteostasis Therapeutics' mailing address is 80 GUEST STREET 5TH FLOOR, BOSTON MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]
MarketBeat Community Rating for Proteostasis Therapeutics (PTI)
MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote "Outperform" if you believe PTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
Proteostasis Therapeutics (NASDAQ:PTI) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Proteostasis Therapeutics in the last 12 months. Their average twelve-month price target is $14.75, suggesting that the stock has a possible upside of 195.59%. The high price target for PTI is $25.00 and the low price target for PTI is $8.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $14.75 | $14.75 | $16.00 | $12.3333 |
| Price Target Upside: | 195.59% upside | 308.59% upside | 257.94% upside | 450.60% upside |
Proteostasis Therapeutics (NASDAQ:PTI) Consensus Price Target History
Proteostasis Therapeutics (NASDAQ:PTI) Analyst Ratings History
Show:
(Data available from 5/21/2016 forward)
Proteostasis Therapeutics (NASDAQ:PTI) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Proteostasis Therapeutics (NASDAQ PTI) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.80%
Institutional Ownership Percentage: 67.11%
Proteostasis Therapeutics (NASDAQ PTI) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/18/2017 | Enterprise Associates 12 New | Major Shareholder | Buy | 2,000,000 | $5.00 | $10,000,000.00 | |  |
| 12/18/2017 | Franklin M Berger | Director | Buy | 60,000 | $5.00 | $300,000.00 | 266,162 | |
| 12/18/2017 | Meenu Chhabra | Insider | Buy | 40,000 | $5.00 | $200,000.00 | 50,218 | |
| 12/14/2017 | Cormorant Asset Management, Ll | Major Shareholder | Sell | 504,027 | $4.88 | $2,459,651.76 | | |
| 3/13/2017 | Fmr Llc | Insider | Sell | 25,000 | $12.94 | $323,500.00 | | |
| 3/10/2017 | Fmr Llc | Insider | Sell | 25,000 | $12.04 | $301,000.00 | | |
| 3/9/2017 | Fmr Llc | Insider | Sell | 29,300 | $12.08 | $353,944.00 | | |
| 3/7/2017 | Fmr Llc | Insider | Sell | 60,000 | $13.01 | $780,600.00 | | |
| 3/3/2017 | Fmr Llc | Insider | Sell | 45,000 | $13.91 | $625,950.00 | | |
| 3/1/2017 | Fmr Llc | Insider | Sell | 45,000 | $14.62 | $657,900.00 | | |
| 2/27/2017 | Fmr Llc | Insider | Sell | 28,000 | $14.60 | $408,800.00 | | |
| 12/16/2016 | Franklin M Berger | Director | Buy | 40,000 | $11.17 | $446,800.00 | 192,162 | |
| 12/13/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 121,301 | $10.82 | $1,312,476.82 | | |
| 12/8/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 44,417 | $10.83 | $481,036.11 | | |
| 12/6/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 87,973 | $10.62 | $934,273.26 | | |
| 12/1/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 170,391 | $10.24 | $1,744,803.84 | | |
| 11/23/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 361,863 | $11.40 | $4,125,238.20 | | |
| 11/14/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 259,500 | $11.05 | $2,867,475.00 | | |
| 11/7/2016 | Cormorant Asset Management, Ll | Major Shareholder | Buy | 327,977 | $8.45 | $2,771,405.65 | | |
| 9/14/2016 | Enterprise Associates 12 New | Major Shareholder | Buy | 461,538 | $13.00 | $5,999,994.00 | | |
| 9/14/2016 | Franklin M Berger | Director | Buy | 69,230 | $13.00 | $899,990.00 | 166,162 | |
| 2/17/2016 | Bioventures Ltd Novartis | Major Shareholder | Buy | 375,000 | $8.00 | $3,000,000.00 | | |
| 2/17/2016 | Franklin M. Berger | Director | Buy | 25,000 | $8.00 | $200,000.00 | 96,932 | |
(Data available from 1/1/2013 forward)
Proteostasis Therapeutics (NASDAQ PTI) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Proteostasis Therapeutics (PTI) Announces Quarterly Earnings Results
www.americanbankingnews.com - May 11 at 10:33 PM |
 | Proteostasis Announces Formation of Independent Steering Committee of Leading ...
www.prnewswire.com - May 9 at 10:08 AM |
 | BRIEF-Proteostasis Announces Formation Of Independent Steering Committee To ...
www.reuters.com - May 9 at 10:08 AM |
 | Proteostasis Announces Formation of Independent Steering Committee of Leading Experts to Advise on the Global Phase 3 Clinical Development Program for PTI-428 in Cystic Fibrosis
finance.yahoo.com - May 8 at 10:01 AM |
| Proteostasis Therapeutics (PTI) Upgraded to Hold by ValuEngine
www.americanbankingnews.com - May 7 at 10:36 PM |
| Proteostasis Therapeutics Inc. (PTI) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 28 at 3:37 AM |
| Lifshitz & Miller LLP Announces Investigation of Acadia Pharmaceuticals Inc., Allegiant Travel Company, Camping ...
www.prnewswire.com - April 24 at 3:53 PM |
| BRIEF-Proteostasis Therapeutics - Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License ...
www.reuters.com - April 24 at 3:53 PM |
| Proteostasis Therapeutics (PTI) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 17 at 8:06 PM |
| BRIEF-Proteostasis Receives Endorsement From Cystic Fibrosis Foundation For Study Of PTI-428 In CF Subjects On Background Symdeko Therapy
www.reuters.com - April 17 at 10:14 AM |
 | TDN on board with Proteostasis' mid-stage study of cystic fibrosis candidate PTI-428
seekingalpha.com - April 17 at 10:14 AM |
| Proteostasis Receives Endorsement from the Cystic Fibrosis Foundation's Therapeutic Development Network for the Study of the Company's Amplifier, PTI-428, in CF Subjects on Background Symdeko™ Therapy
finance.yahoo.com - April 17 at 10:14 AM |
| Is the Options Market Predicting a Spike in Proteostasis Therapeutics (PTI) Stock?
finance.yahoo.com - April 16 at 10:01 AM |
| Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic ...
www.prnewswire.com - April 5 at 3:53 PM |
 | PTI INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Proteostasis ...
www.businesswire.com - April 5 at 8:22 AM |
 | Proteostasis Therapeutics (PTI) Granted FDA Fast Track Designation for Triple Combination Program in Patients with ...
www.streetinsider.com - April 5 at 8:22 AM |
| Proteostasis Therapeutics receives Fast Track Designation for triple combination program in patients with cystic fibrosis
seekingalpha.com - April 4 at 5:36 PM |
| Pre-Open Stock Movers 04/04: (PTI) (HCC) (PLAY) Higher; (CLDR) (AYI) (SGH) Lower (more...)
www.streetinsider.com - April 4 at 5:36 PM |
 | Proteostasis Climbs on FDA Designation
www.baystreet.ca - April 4 at 5:36 PM |
 | Proteostasis Therapeutics Wins Big With FDA Decision
www.msn.com - April 4 at 5:36 PM |
| Proteostasis Therapeutics Receives FDA Fast Track Designation for Triple Combination Program in Patients with Cystic Fibrosis
finance.yahoo.com - April 4 at 5:36 PM |
| Proteostasis shares surge 12% on FDA 'fast track' designation for cystic fibrosis treatment
finance.yahoo.com - April 4 at 5:36 PM |
| Proteostasis Therapeutics Inc (PTI) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 3 at 3:08 AM |
| Proteostasis Therapeutics Inc (PTI) Short Interest Up 249.8% in March
www.americanbankingnews.com - March 29 at 2:22 AM |
| Proteostasis Therapeutics (PTI) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 28 at 10:23 PM |
| Proteostasis inks $50M stock sale agreement with Leerink
seekingalpha.com - March 26 at 10:56 AM |
| PROTEOSTASIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Proteostasis Therapeutics, Inc. To Contact The Firm
finance.yahoo.com - March 23 at 9:49 AM |
| Glancy Prongay & Murray LLP Announces Investigation on Behalf of Proteostasis Therapeutics, Inc. Investors (PTI) - Business Wire (press release)
www.businesswire.com - March 22 at 4:00 PM |
| Glancy Prongay & Murray LLP Continues Investigation on Behalf of Proteostasis Therapeutics, Inc. Investors (PTI) - Business Wire (press release)
www.businesswire.com - March 22 at 4:00 PM |
| Proteostasis Therapeutics (PTI) Announces Withdrawal of Equity Offering Due to Market Conditions
www.streetinsider.com - March 22 at 10:00 AM |
| Glancy Prongay & Murray LLP Announces Investigation on Behalf of Proteostasis Therapeutics, Inc. Investors (PTI)
finance.yahoo.com - March 22 at 10:00 AM |
| Proteostasis Therapeutics (PTI) Announces Withdrawal of Equity Offering Due to Market Conditions - StreetInsider.com
www.streetinsider.com - March 21 at 4:08 PM |
| Proteostasis Therapeutics' FDA Breakthrough Therapy Designation Gives It An Edge - Seeking Alpha
seekingalpha.com - March 21 at 4:08 PM |
| Bragar Eagel & Squire, PC is Investigating Proteostasis Therapeutics, Inc. (PTI) on Behalf of Stockholders and ... - Business Wire (press release)
www.businesswire.com - March 21 at 4:08 PM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Proteostasis Therapeutics ... - PR Newswire (press release)
www.prnewswire.com - March 21 at 4:08 PM |
| Scott+Scott Attorneys at Law LLP Announces Investigation into Proteostasis Therapeutics, Inc. (PTI) - PR Newswire (press release)
www.prnewswire.com - March 21 at 4:08 PM |
| Scott+Scott Attorneys at Law LLP Announces Investigation into Proteostasis Therapeutics, Inc. (PTI)
finance.yahoo.com - March 21 at 4:08 PM |
| Bragar Eagel & Squire, P.C. is Investigating Proteostasis Therapeutics, Inc. (PTI) on Behalf of Stockholders and Encourages Investors to Contact the Firm
finance.yahoo.com - March 21 at 4:08 PM |
| Proteostasis Therapeutics (PTI) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 21 at 1:29 PM |
 | Sahm Adrangi's Kerrisdale Capital Issues Negative Report on Proteostasis Therapeutics, Inc., and Announces Conference-Call Schedule
www.bizjournals.com - March 21 at 11:05 AM |
| 7 Biotech Movers To Watch Today: Prothena, Proteostasis, Global Blood Therapeutics And More
www.msn.com - March 21 at 11:05 AM |
| Proteostasis won't complete public offering after short report; shares rise 14%
finance.yahoo.com - March 21 at 11:05 AM |
| ValuEngine Downgrades Proteostasis Therapeutics (PTI) to Strong Sell
www.americanbankingnews.com - March 21 at 12:48 AM |
| Analyzing Agenus (AGEN) and Proteostasis Therapeutics (PTI)
www.americanbankingnews.com - March 20 at 5:14 PM |
| Proteostasis Therapeutics, Inc.: Hyped-Up Lung Data? Just A Lot Of Hot Air - Seeking Alpha
seekingalpha.com - March 20 at 4:02 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Proteostasis Therapeutics ... - PR Newswire (press release)
www.prnewswire.com - March 20 at 4:02 PM |
| Biotech short seller eviscerates Proteostasis in new report, dinging shares
finance.yahoo.com - March 20 at 4:02 PM |
| Proteostasis Therapeutics shares tank 18% after Kerrisdale Capital puts out short report
finance.yahoo.com - March 20 at 4:02 PM |
| SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Proteostasis Therapeutics, Inc. (PTI)
finance.yahoo.com - March 20 at 4:02 PM |
| SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Proteostasis Therapeutics, Inc. - PTI
finance.yahoo.com - March 20 at 4:02 PM |
Proteostasis Therapeutics (NASDAQ:PTI) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Proteostasis Therapeutics (NASDAQ:PTI) Income Statement, Balance Sheet and Cash Flow Statement
Proteostasis Therapeutics (NASDAQ PTI) Stock Chart for Monday, May, 21, 2018
Loading chart…
